What are the latest funding trends in biotechnology?

SUMMARY

Biotechnology funding is stronger right now, but the rebound is more selective and concentrated than the 20.7% jump in total capital suggests.

Current YTD funding reached 287 deals and 281 unique companies, versus 272 deals and 270 companies over the same stretch last year. The market has widened a little, not just recycled larger checks through the same names.

The headline dollar growth overstates the improvement. Removing rounds above $100 million leaves capital up 6.9%, and capital from rounds below $50 million is up 9.3%, so the underlying market still looks healthier even after the biggest deals are stripped out.

The strongest shift is toward follow-on capital. First financings increased from 67 to 75, but first-financing dollars fell to $3.25 billion while follow-on capital jumped to $15.51 billion and the median follow-on round reached $46 million.

Series B has become the main capital hotspot. It represents 23% of deals but 37.6% of funding, helped by Isomorphic Labs' $2.1 billion round but also by a broader increase in large mid-stage checks.

Early-stage biotech has not disappeared. Early-stage rounds still represent roughly the same share of known-stage deals as in the previous two comparable periods; investors are simply concentrating far more money once companies clear technical, clinical or commercial milestones.

Therapeutics Discovery Platforms now absorb 72.1% of deals and 86.7% of capital. Diagnostics are losing ground more consistently, while gene editing looks more like a normalization after an unusually strong previous year than a category-wide collapse.

The $50 million to $100 million round is becoming much more normal: 74 such financings were recorded now, versus 66 last year and 50 two years ago. Sub-$5 million deals also increased, so the market is stretching at both ends.

Geographically, China is gaining real breadth, with 29 financings versus 16 last year and 12 two years ago. Europe remains active too, but its capital total is heavily distorted by one exceptional UK round, so deal count gives a cleaner picture there than dollars alone.

Overall, biotech has already raised about four-fifths of the capital recorded in each of the previous two full years while completing only about seven-tenths of their deal counts. The current market is capital-heavy, evidence-driven and moderately broader, but total dollars alone still make it look hotter than the rest of the data supports.